Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next

John Leonard, Intellia CEO April 27, 2026 11:30 AM EDT PeopleR&D Q&A: In­tel­lia CEO talks first Phase 3 CRISPR read­out and what’s next Lei Lei Wu News Reporter Ryan Cross Senior Science Correspondent In­tel­lia Ther­a­peu­tics re­port­ed this morn­ing on the Phase 3 suc­cess of a gene edit­ing treat­ment for hered­i­tary an­gioede­ma, a dis­ease that caus­es un­pre­dictable, dis­fig­ur­ing and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER